Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A diffuse large B-cell lymphoma that is categorized as BN2 with high probability by the LymphGen algorithm. This is based on a combination of genetic features and BN2 DLBCLs often, but do not always, have a translocation involving the BCL6 locus and/or some combination of mutations affecting NOTCH2, TNFAIP3, BCL10 and UBE2A. This subgroup also commonly has mutations due to aberrant somatic hypermutation affecting CD70, which can be coding or non-coding.
Biomarker and diagnostic research for BN2 diffuse large B-cell lymphoma has been reported in the published literature.
No clinical trials have been registered for BN2 diffuse large B-cell lymphoma.
13 publications have been identified in PubMed for BN2 diffuse large B-cell lymphoma. Research spans Basic Science / Preclinical (46%), Diagnostic / Biomarker (31%), and Clinical Trial Publication (8%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 6 | 46% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 12:48 AM UTC
Common questions about BN2 diffuse large B-cell lymphoma
Testing and diagnosis research
4 |
31% |
Clinical study results | 1 | 8% |
Disease patterns and progression | 1 | 8% |
New treatment approaches | 1 | 8% |
Yim J (2026). [PMID: 41544233](https://pubmed.ncbi.nlm.nih.gov/41544233/). *Blood Adv*. [Diagnostic / Biomarker]
Pelzer B (2026). [PMID: 42013317](https://pubmed.ncbi.nlm.nih.gov/42013317/). *Cancer Discov*. [Basic Science / Preclinical]
Liang JH (2026). [PMID: 41776568](https://pubmed.ncbi.nlm.nih.gov/41776568/). *BMC Med*. [Diagnostic / Biomarker]
Rosemarie Q (2026). [PMID: 41958986](https://pubmed.ncbi.nlm.nih.gov/41958986/). *bioRxiv*. [Basic Science / Preclinical]
Shen YG (2025). [PMID: 40715072](https://pubmed.ncbi.nlm.nih.gov/40715072/). *Signal Transduct Target Ther*. [Clinical Trial Publication]
Pomares AA (2025). [PMID: 40067847](https://pubmed.ncbi.nlm.nih.gov/40067847/). *PLoS One*. [Basic Science / Preclinical]
An S (2025). [PMID: 41466441](https://pubmed.ncbi.nlm.nih.gov/41466441/). *BMC Cancer*. [Basic Science / Preclinical]
Dondolin R (2025). [PMID: 40629066](https://pubmed.ncbi.nlm.nih.gov/40629066/). *Leukemia*. [Gene Therapy / Novel Therapeutics]
Moia R (2025). [PMID: 39825831](https://pubmed.ncbi.nlm.nih.gov/39825831/). *Blood Adv*. [Epidemiology / Natural History]
Miljkovic M (2025). [PMID: 40272175](https://pubmed.ncbi.nlm.nih.gov/40272175/). *Radiol Oncol*. [Diagnostic / Biomarker]
AI-curated news mentioning BN2 diffuse large B-cell lymphoma
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.